Key Development Forge Biologics, a member of Ajinomoto Bio-Pharma Services, has entered a development and cGMP manufacturing partnership with Restore... Read more
Category: Uncategorized
AMGEN’S $74 MILLION SETTLEMENT PUTS CORPORATE GOVERNANCE AND TAX TRANSPARENCY UNDER THE INVESTOR SPOTLIGHT
Key Development Amgen has agreed to pay US$74 million to settle a shareholder class-action lawsuit alleging that the biotechnology company... Read more
FDA PILOT PROGRAM FOR VETERINARY DRUGS SIGNALS A BROADER PUSH TO REBUILD U.S. PHARMACEUTICAL MANUFACTURING
Key Development The U.S. Food and Drug Administration (FDA) has launched a pilot program designed to encourage domestic manufacturing of... Read more
NOVARTIS NAVIGATES THE PATENT CLIFF WITH STRONG EARNINGS, BUT THE NEXT GROWTH TEST HAS JUST BEGUN
Key Development Novartis delivered a stronger-than-expected second-quarter performance, reporting core operating profit above market forecasts despite intensifying generic competition against... Read more
ELI LILLY’S $3.8 BILLION ATAIBECKLEY ACQUISITION SIGNALS BIG PHARMA’S NEXT BET ON NEUROSCIENCE
Key Development Eli Lilly's agreement to acquire AtaiBeckley for up to US$3.8 billion represents more than another biotechnology acquisition it... Read more
POLYPID AND AZURITY PARTNER TO ADVANCE SURGICAL INFECTION PREVENTION IN NORTH AMERICA
Key Development The exclusive commercial partnership between PolyPid and Azurity Pharmaceuticals marks more than a regional licensing agreement it reflects... Read more
FEDERAL SCRUTINY OF MEDICAID FUNDING SIGNALS A NEW ERA OF FINANCIAL ACCOUNTABILITY IN U.S. HEALTHCARE
Key Development A temporary pause in selected Medicaid payments to California has brought renewed attention to one of the most... Read more
U.S. MEDICAID PAYMENT PAUSE RAISES NEW QUESTIONS ABOUT FEDERAL OVERSIGHT, STATE FINANCING, AND HEALTHCARE STABILITY
Key Development The decision by U.S. federal health authorities to temporarily suspend portions of Medicaid payments to California marks another... Read more
NOVO NORDISK AND ELI LILLY’S LEGAL CLASH SIGNALS A NEW COMPETITIVE FRONT IN THE GLP-1 ERA
Key Development Competition in the obesity and diabetes market has entered a new phase where legal strategy is becoming as... Read more









